Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators. van der Heijden MS, et al. Among authors: patel my. N Engl J Med. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22. N Engl J Med. 2023. PMID: 37870949 Clinical Trial.
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
Brodtkorb TH, Knight C, Kamgar F, Teitsson S, Kurt M, Patel MY, Poretta T, Mamtani R, Palmer S. Brodtkorb TH, et al. Among authors: patel my. J Med Econ. 2024 Jan-Dec;27(1):543-553. doi: 10.1080/13696998.2024.2329019. Epub 2024 Apr 4. J Med Econ. 2024. PMID: 38470512 Free article.
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo.
Teitsson S, Brodtkorb TH, Kurt M, Patel MY, Poretta T, Knight C, Kamgar F, Palmer S. Teitsson S, et al. Among authors: patel my. J Med Econ. 2024 Jan-Dec;27(1):473-481. doi: 10.1080/13696998.2024.2322394. Epub 2024 Mar 25. J Med Econ. 2024. PMID: 38385621 Free article.
Erratum to 'Lipid Treatment and Goal Attainment Characteristics among Persons with Atherosclerotic Cardiovascular Disease in the United States' [American Journal of Preventive Cardiology 1C (2020) 100010].
Klimchak AC, Patel MY, Iorga ŞR, Kulkarni N, Wong ND. Klimchak AC, et al. Among authors: patel my. Am J Prev Cardiol. 2021 Mar 29;5:100160. doi: 10.1016/j.ajpc.2021.100160. eCollection 2021 Mar. Am J Prev Cardiol. 2021. PMID: 34374692 Free PMC article.
17 results